Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Differentially expressed genes in metastatic advanced Egyptian bladder cancer.
Asian Pac J Cancer Prev. 2015;16(8):3543-9. doi: 10.7314/apjcp.2015.16.8.3543.
Asian Pac J Cancer Prev. 2015.
PMID: 25921176
Free article.
Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial-an update.
Haggag R, Farag K, Abu-Taleb F, Shamaa S, Zekri AR, Elbolkainy T, Khaled H.
Haggag R, et al.
Med Oncol. 2014 Jan;31(1):811. doi: 10.1007/s12032-013-0811-5. Epub 2013 Dec 12.
Med Oncol. 2014.
PMID: 24338168
Clinical Trial.
Item in Clipboard
Hepatitis C virus and non-Hodgkin's lymphomas: A minireview.
Khaled H, Abu-Taleb F, Haggag R.
Khaled H, et al.
J Adv Res. 2017 Mar;8(2):131-137. doi: 10.1016/j.jare.2016.11.005. Epub 2016 Dec 12.
J Adv Res. 2017.
PMID: 28149648
Free PMC article.
Review.
Item in Clipboard
Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen.
Khaled HM, Abdelhamid TM, Abu-Taleb FM, El-Hifnawi NM, Waley AB.
Khaled HM, et al. Among authors: abu taleb fm.
Future Sci OA. 2019 Aug 28;5(9):FSO414. doi: 10.2144/fsoa-2019-0076.
Future Sci OA. 2019.
PMID: 31608153
Free PMC article.
Item in Clipboard
Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
El Shorbagy S, abuTaleb F, Labib HA, Ebian H, Harb OA, Mohammed MS, Rashied HA, Elbana KA, Haggag R.
El Shorbagy S, et al.
J Gastrointest Cancer. 2021 Mar;52(1):269-279. doi: 10.1007/s12029-020-00389-w.
J Gastrointest Cancer. 2021.
PMID: 32212089
Clinical Trial.
Item in Clipboard
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.
Davies C, et al.
Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1.
Lancet. 2013.
PMID: 23219286
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite